Pekka Kallio

Pekka brings Rappta with thirty years of experience in academia, biotech, pharma, and FIMEA/EMA. While in Orion Pharma he played a key role in setting up oncology research. During his tenure as Head of Oncology Research, his organization delivered more than ten clinical candidates. These include Darolutamide (Nubeqa) now marketed globally for castration-resistant prostate cancer, as well as other innovative targeted treatments that are under clinical phase I-II development for solid tumors. Before joining Rappta, Pekka worked at the Finnish Medicine Agency/EMA. His duties included the review of clinical trial applications and monitoring of clinical trials for oncology drugs, as well as providing scientific advice both at EMA and national levels. He also assessed oncology marketing authorization applications for EMA. Pekka received his Ph.D. from the University of Helsinki and was a postdoctoral fellow at Karolinska Institute (Cell and Molecular Biology, Medical Nobel Institute). He is an Adjunct Professor of Cell and Molecular Biology at the University of Helsinki.